Business Wire

FourKites Signs on as Collaborator to Consortium of Supply Chain Leaders Working to Streamline Scheduling Technology Across the Logistics Industry

Share

Leading real-time supply chain visibility provider FourKites® today announced its role as a Collaborator in the Scheduling Standards Consortium (SSC) as the first real-time visibility platform participating. FourKites joins organisations involved with the SSC — including Arrive Logistics, BlueYonder, Coyote Logistics, DHL, e2open, Echo, J.B. Hunt Transport, Lineage, Mastery, One Network Enterprises, Oracle, Ryder, TI NTG, Uber Freight, Werner and Worldwide Express — which aims to foster greater efficiency within the supply chain technology landscape.

Freight scheduling has been a pervasive problem for the supply chain, compounded by the past decade’s tremendous growth and diversification in scheduling solutions. Shippers and carriers today are responsible for juggling dozens of methods of scheduling freight with shippers, each with their own interface and API, which creates friction and inefficiencies throughout the supply chain.

In response to this challenge, J.B. Hunt and Uber Freight joined forces in 2022 to establish the SSC, to create the first universal appointment scheduling standard in the form of an API. With many leading organisations now involved and driving the Standard forward, the SSC’s goal is to simplify the integration of systems across the fragmented ecosystem between shippers, carriers and intermediaries to create a more efficient appointment scheduling process. The SSC has endorsed a universal standard for the API, released October 2, 2023, which eliminates the need for multiple interfaces and allows carriers to interact through a single interface.

“Embracing a universal scheduling API unlocks seamless coordination across supply chains,” explains Viral Parekh, Head of Logistics Operations at The Kraft Heinz Company. “As more companies endorse this unified approach, we pave the way for unparalleled system efficiency, streamlining operations and driving transformative growth throughout the industry.”

FourKites is collaborating with the SSC because of its proven commitment to optimising ecosystem performance, carrier success and building a more user-friendly operating environment. In addition, FourKites’ robust customer base and recognised industry leadership enables it to play a role in developing the API and accelerating adoption across its customer and partner network. With over 100,000 appointments scheduled in the platform every month, Slot Manager is one of FourKites’ fastest-growing products, as it significantly eliminates the friction associated with manual time slot booking.

“We’re thrilled to participate in this consortium of industry heavy-hitters,” said Mathew Elenjickal, founder and CEO of FourKites. “A single API between our Slot Manager solution and our shippers’ carrier networks will create a frictionless operating environment for everyone involved, and will make FourKites customers Shippers of Choice, with lower cost to serve and a reliable, reputable integration.”

The SSC’s main objectives are to define the API standard for sharing scheduling information, eliminate manual processes by automating interactions where possible, implement standardised interfaces and integrations across core platforms, and advocate the standard across the industry.

About the Scheduling Standards Consortium (SSC)

Founded in 2022 by Convoy, J.B. Hunt and Uber Freight, the Scheduling Standards Consortium (SSC) was established to create freight appointment scheduling standards that provide consistent visibility into the supply chain. Together with shippers, carriers and intermediaries, the SSC aims to simplify the integration of systems across the fragmented ecosystem and generate efficiency across the freight industry. To learn more, visit www.FreightAPIs.org.

About FourKites

Leading global supply chain visibility platform FourKites® empowers business leaders with comprehensive visibility into transportation, yards, warehouses, stores and beyond. Tracking more than 3.2 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,500 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Scott Johnston
European PR Director, FourKites
scott.johnston@fourkites.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release

Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye